2024 SAMPLE CHARACTERISTICS

IDRS Illicit Drug Reporting System

In 2024, 100 participants, recruited from Canberra, ACT, were interviewed.



48 years **Male**

The median age in 2024 was 48, and 70% identified as male.



In the 2024 sample, 91% were unemployed and 12% had no fixed address.

Injected heroin

Injected methamphetamine

Injected other illicit or non-prescribed drugs

Participants were recruited on the basis that they had injected drugs at least monthly in the previous 6 months.

INJECTING-RELATED RISKS AND HARMS



In 2024, few participants (n≤5) reported receptive sharing, and distributive sharing in the past month.



44% of participants reported re-using their own needles in the past month, a significant increase relative to 2023 (26%)



Percentage who reported injecting someone else after injecting themselves in the past month.



31% of participants reported having an injection-related health issue in the past month, stable from 2023 (28%).

*p<0.050; **p<0.010; ***p<0.001

OTHER HARMS



In 2024, 70% reported using two or more drugs on the day preceding interview: the most commonly used combination of drug classes was cannabis and simulants/opioids (17%).



Past year non-fatal overdose remained stable in 2024, relative to 2023.

In 2024, 58% of participants reported a mental health problem in the 6 months preceding interview.



Among those who reported a mental health problem, the three most common mental health issues were depression, anxiety and PTSD.

NALOXONE AND OTHER HARM REDUCTION STRATEGIES



Knowledge of take-home naloxone and past year naloxone obtainment remained stable in 2024.



Among those who were aware of naloxone, 52% reported ever using naloxone to resuscitate someone who had overdosed, with 32% having done so in the past year.



Percentage who reported that they or someone else had tested the content and/or purity of their illicit drugs in Australia in the past year.



Percentage who reported current drug treatment and health service access for AOD support in the past six months.

HEROIN

IDRS Illicit Drug Reporting System

Past 6 month use of heroin remained stable in 2024 (74%) relative to 2023 (81%)

78%

Of those who had recently consumed heroin, 78% reported weekly or more frequent use, stable from 2023 (79%).

$80 2023 $80 2024

The median reported price for a point of heroin.

91% 2024

98% 2023

Percentage who perceived heroin as being 'easy' or 'very easy' to obtain.

METHAMPHETAMINE

FORM of methamphetamine



Past 6 month use remained stable in 2024 relative to 2023.

79%

Of those who had recently used any form of methamphetamine, 79% reported weekly or more frequent use, stable from 2023 (71%).

$50 2023 $50 2024

The median reported price for a point of methamphetamine crystal.

96% 2024

92% 2023

Percentage who perceived methamphetamine crystal as being 'easy' or 'very easy' to obtain.

CANNABIS AND/OR CANNABINOID-RELATED PRODUCTS

Past 6 month use remained stable in 2024 (74%) relative to 2023 (75%).

56%

Of those who had recently used non-prescribed cannabis/cannabinoid-related products, 56% reported daily use, stable from 2023 (58%).

Of participants who had consumed non-prescribed cannabis and/or cannabinoid-related products in the last 6 months, 97% had smoked it.



Percentage who perceived cannabis/cannabinoid-related products as being 'easy' or 'very easy' to obtain.

PAST 6 MONTH USE OF OTHER DRUGS

Non-prescribed morphine



Non-prescribed fentanyl



Non-prescribed pregabalin



GHB/GBL/1,4-BD